Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Blood (2025) 146 (Supplement 1): 81.

https://doi.org/10.1182/blood-2025-81

Published: 2025

Journal Articles

Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax

Aarya Murali, Zahra AlHaj Issa, Cristiano Machado De Freitas, Akhil Rajendra, Marta Davidson, Aniket Bankar, Hassan Sibai, Maria Perusini, Steven Chan, Aaron Schimmer, Mark Minden, Karen W.L. Yee, Andre Schuh, Vikas Gupta, Dawn Maze, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 3508.

https://doi.org/10.1182/blood-2025-3508

Published: 2025

Journal Articles

Prognostic impact of molecular genetic and cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with azacitidine and venetoclax: A real-world cohort study

Cristiano Machado De Freitas, Aarya Murali, Zahra AlHaj Issa, Aniket Bankar, Hassan Sibai, Maria Perusini, Aaron Schimmer, Mark Minden, Steven Chan, Karen W.L. Yee, Andre Schuh, Vikas Gupta, Dawn Maze, Marta Davidson, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 4776.

https://doi.org/10.1182/blood-2025-4776

Published: 2025

Journal Articles

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

Josephine Anne Lucero, Maria Perusini, Aniket Bankar, Marta Davidson, Guillaume Richard-Carpentier, Aaron Schimmer, Andre Schuh, Dawn Maze, Karen W.L. Yee, Mark Minden, Steven Chan, Jose-Mario Capo-Chichi, Vikas Gupta, Hassan Sibai, Anne Tierens, Dennis Kim

Blood (2025) 146 (Supplement 1): 7051.

https://doi.org/10.1182/blood-2025-7051

Published: 2025

Journal Articles

Real-world evidence evaluation of the safety and efficacy of intensive chemotherapy with or without gemtuzumab ozogamicin (GO) in patients with newly diagnosed Acute Myeloid Leukemia (AML) and favorable or intermediate risk cytogenetics

Elizabeth Herrity, Dawn Maze, Marta Davidson, Aniket Bankar, Maria Perusini, Hassan Sibai, Steven Chan, Aaron Schimmer, Mark Minden, Karen W.L. Yee, Andre Schuh, Vikas Gupta, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 5240.

https://doi.org/10.1182/blood-2025-5240

Published: 2025

Journal Articles

Mixed phenotype acute leukemia: Clinical characteristics and real-world outcomes

Ana Patiño, Hong Chang, Mark Turingan, Aniket Bankar, Jonathan Wei, Marta Davidson, Guillaume Richard-Carpentier, Mark Minden, Andre Schuh, Karen W.L. Yee, Vikas Gupta, Dawn Maze, Steven Chan, Aaron Schimmer, Claire Andrews, Hassan Sibai, Maria Perusini

Blood (2025) 146 (Supplement 1): 3330.

https://doi.org/10.1182/blood-2025-3330

Published: 2025

Journal Articles

FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML

Akhil Rajendra, Dawn Maze, Aniket Bankar, Steven Chan, Marta Davidson, Vikas Gupta, Mark Minden, Maria Perusini, Guillaume Richard-Carpentier, Aaron Schimmer, Andre Schuh, Elliot Smith, Karen W.L. Yee, Hassan Sibai

Blood (2025) 146 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2025-1672

Published: 2025

Journal Articles

Comprehensive analyses of patient-reported outcomes from the phase 3 VERIFY study of rusfertide or placebo plus current standard of care for polycythemia vera

Aniket Bankar, Andrew Kuykendall, Naveen Pemmaraju, Kristen Pettit, Joseph Shatzel, Alessandro Lucchesi, Valentín García Gutiérrez, Harinder Gill, Joseph Scandura, Francesca Palandri, Matthew Reaney, Cristina Ivanescu, Christina Daskalopoulou, Phil Dinh, Sarita Khanna, Suneel Gupta, Arturo Molina, David Cella

Blood (2025) 146 (Supplement 1): 5588.

https://doi.org/10.1182/blood-2025-5588

Published: 2025

Journal Articles

Should dermatologic examinations become routine standard of care in patients with polycythemia vera? Observations from the phase 3 VERIFY study prior to rusfertide exposure

Joseph Shatzel, Andrew Kuykendall, Aniket Bankar, Naveen Pemmaraju, Kristen Pettit, Alessandro Lucchesi, Valentín García Gutiérrez, Antonieta Sosa, A. Peter Morello, Pedro Oyuela, Phil Dinh, Arturo Molina

Blood (2025) 146 (Supplement 1): 5587.

https://doi.org/10.1182/blood-2025-5587

Published: 2025

Journal Articles

Clinical Relevance of NPM1 Quantitative PCR As Standard of Care with Different Cut-Off Values on Treatment Outcomes in NPM1-Mutated Acute Myeloid Leukemia Patients

Donna Zhe Sian Eng, Andre C. Schuh, Aniket Bankar, Marta Beata Davidson, Guillaume Richard-Carpentier, Hassan Sibai, Dawn C. Maze, Karen Yee, Aaron D Schimmer, Vikas Gupta, Tracy Stockley, Jose-Mario Capo-Chichi, Chen Steven, Dennis Dong Hwan Kim

Blood (2024) 144 (Supplement 1): 6172.

https://doi.org/10.1182/blood-2024-211783

Published: 2024

Journal Articles

What Is the Prognostic Relevance of Responses Less Than a CR(Sub-CR) to Initial AML Treatment?

Akhil Rajendra, Elliot Smith, Eshetu Atenafu, Aniket Bankar, Steven M. Chan, Marta Beata Davidson, Vikas Gupta, Mark D. Minden, Maria Agustina Perusini, Guillaume Richard-Carpentier, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Dawn C. Maze

Blood (2024) 144 (Supplement 1): 5193.

https://doi.org/10.1182/blood-2024-208884

Published: 2024

Journal Articles

FRAIL-HRU-AML: Impact of Frailty Assessment on Health Resource Utilization in Acute Myeloid Leukemia Patients: A Population-Based Study from Ontario, Canada

Gopila Gupta, Sho Podolsky, Ning Liu, Matthew C. Cheung, Aniket Bankar

Blood (2024) 144 (Supplement 1): 449.

https://doi.org/10.1182/blood-2024-209217

Published: 2024

Journal Articles

Intensive Chemotherapy Vs. Azacitidine + Venetoclax for AML with Secondary Mutations

Elliot Smith, Akhil Rajendra Kurup, Eshetu Atenafu, Aniket Bankar, Steven M. Chan, Marta Beata Davidson, Vikas Gupta, Mark D. Minden, Guillaume Richard-Carpentier, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Dawn C. Maze

Blood (2024) 144 (Supplement 1): 1483.

https://doi.org/10.1182/blood-2024-202069

Published: 2024

Journal Articles

FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience

Eshrak Al-Shaibani, Marta Beata Davidson, Aniket Bankar, Steven M. Chan, Hassan Sibai, Dawn C. Maze, Aaron D Schimmer, Mark D. Minden, Karen Yee, Vikas Gupta, Andre C. Schuh, Guillaume Richard-Carpentier

Blood (2024) 144 (Supplement 1): 4273.

https://doi.org/10.1182/blood-2024-209476

Published: 2024

Journal Articles

Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with IDH2 -Mutated Relapsed/Refractory Myeloid Malignancies

Guillaume Richard-Carpentier, Gopila Gupta, Charina Cameron, Severine Cathelin, Aniket Bankar, Marta Beata Davidson, Vikas Gupta, Dawn C. Maze, Mark D. Minden, Tracy Murphy, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Courtney D. DiNardo, Joseph Brandwein, Caroline Jane McNamara, Steven M. Chan

Blood (2023) 142 (Supplement 1): 159.

https://doi.org/10.1182/blood-2023-188341

Published: 2023

Journal Articles

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)

Josephine Anne Lucero, Aniket Bankar, Marta Beata Davidson, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Dawn C. Maze, Karen Yee, Mark D. Minden, Steven M. Chan, Jonas Mattsson, Rajat Kumar, Vikas Gupta, Jose-Mario Capo-Chichi, Tracy Stockley, Hassan Sibai, Anne Maria Tierens, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 1595.

https://doi.org/10.1182/blood-2023-190694

Published: 2023

Journal Articles

Comparison of Clinical Outcomes between Transplant and Non-Transplant Therapies in Myelofibrosis Following Failure of First-Line JAK-Inhibitor

James T. England, Eshetu G. Atenafu, James A. Kennedy, Burhan Goraya, Verna Cheung, Taylor Nye, Karine Gauthier, Marta B. Davidson, Aniket Bankar, Hassan Sibai, Dawn Maze, Auro Viswabandya, Vikas Gupta

Blood (2022) 140 (Supplement 1): 9724–9725.

https://doi.org/10.1182/blood-2022-165272

Published: 2022

Journal Articles

Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers

Josephine Anne Lucero, Brayan Merchán, Osamah Jamal S. Jarallah, Aniket Bankar, Steven M. Chan, Marta B. Davidson, Vikas Gupta, Dawn Maze, Mark D. Minden, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Karen Yee, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3166–3168.

https://doi.org/10.1182/blood-2022-168488

Published: 2022

Journal Articles

Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol

Maria Agustina Perusini, Jad Sibai, Eshetu G. Atenafu, Aniket Bankar, Mark D. Minden, Vikas Gupta, Dawn Maze, Marta B. Davidson, Steven M. Chan, Aaron D. Schimmer, Guillaume Richard-Carpentier, Josephine Anne Lucero, Claire Andrews, Dennis Dong Hwan Kim, Karen Yee, Andre C. Schuh, Hassan Sibai

Blood (2022) 140 (Supplement 1): 6039–6041.

https://doi.org/10.1182/blood-2022-169406

Published: 2022

Journal Articles

Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience

Salman Alharbi, Maria Agustina Perusini, Sita Bhella, Mark D. Minden, Dawn Maze, Vikas Gupta, Aaron D. Schimmer, Andre C. Schuh, Karen Yee, Steven M. Chan, Aniket Bankar, Marta B. Davidson, Guillaume Richard-Carpentier, Jad Sibai, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3187–3188.

https://doi.org/10.1182/blood-2022-168662

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax

Prognostic impact of molecular genetic and cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with azacitidine and venetoclax: A real-world cohort study

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

Real-world evidence evaluation of the safety and efficacy of intensive chemotherapy with or without gemtuzumab ozogamicin (GO) in patients with newly diagnosed Acute Myeloid Leukemia (AML) and favorable or intermediate risk cytogenetics

Mixed phenotype acute leukemia: Clinical characteristics and real-world outcomes

FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML

Comprehensive analyses of patient-reported outcomes from the phase 3 VERIFY study of rusfertide or placebo plus current standard of care for polycythemia vera

Should dermatologic examinations become routine standard of care in patients with polycythemia vera? Observations from the phase 3 VERIFY study prior to rusfertide exposure

Clinical Relevance of NPM1 Quantitative PCR As Standard of Care with Different Cut-Off Values on Treatment Outcomes in NPM1-Mutated Acute Myeloid Leukemia Patients

What Is the Prognostic Relevance of Responses Less Than a CR(Sub-CR) to Initial AML Treatment?

FRAIL-HRU-AML: Impact of Frailty Assessment on Health Resource Utilization in Acute Myeloid Leukemia Patients: A Population-Based Study from Ontario, Canada

Intensive Chemotherapy Vs. Azacitidine + Venetoclax for AML with Secondary Mutations

FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience

Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with IDH2 -Mutated Relapsed/Refractory Myeloid Malignancies

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)

Comparison of Clinical Outcomes between Transplant and Non-Transplant Therapies in Myelofibrosis Following Failure of First-Line JAK-Inhibitor

Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers

Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol

Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only